Journals / Veterinary Sciences and Practices / 2019 / Cilt: 14 Sayı: 1

Determination of Cytotoxic and Genotoxic Effects of Parietin in HepG2 Hepatocellular Carcinoma Cells

Parietinin HepG2 Hepatoselüler Karsinom Hücrelerinde Sitotoksik ve Genotoksik Etkisinin Belirlenmesi

Pages
29–37
Publication Date
2019-04-28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, this effect of parietin should be supported by further studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hepatocellular carcinoma (HCC) originating from liver cells is the third leading cause of cancer-related death.
📊
Key Findings & Data:In this study, it was aimed to investigate the cytotoxic and genotoxic effect of parietin on HepG2 hepatocellular carcinoma cells.
💡
Conclusion & Impact:However, this effect of parietin should be supported by further studies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:HepG2 hücre hattı · Komet Analizi · Parietin

Abstract

Hepatocellular carcinoma (HCC) originating from liver cells is the third leading cause of cancer-related death. Parietin is an anthraquinone, isolated from some plants such as Rheum ribes L. Cytotoxicity and genotoxicity tests have an important role in the assessment of heritable and carcinogenic risks. In this study, it was aimed to investigate the cytotoxic and genotoxic effect of parietin on HepG2 hepatocellular carcinoma cells. HepG2 cells were cultured in appropriate culture medium. Then, different concentrations of parietin (final concentrations in the well to be 25-1000 μM) were added to the cells and they were allowed to incubate for 24-48 hours. Cell viability and genotoxic effect were determined by using XTT method and comet assay, respectively. The IC50 concentration of parietin was detected as 25 μM at the 48 hour in HepG2 cells. According to the comet assay, there was no statistically significant increase DNA tail length, DNA tail intensity and DNA tail moment in parietin treated cell groups compared to control groups (p>0.05). In this study, it has been shown that parietin has cytotoxic at low dose, but has not genotoxic effect in HepG2 cells, and as a result parietin was found to be useful in combination with other drugs in the treatment of HepG2 cells. However, this effect of parietin should be supported by further studies.

Özet

Hepatoselüler karsinom (HCC) karaciğer hücrelerinden köken kansere bağlı ölümlerde de üçüncü sırada yer alan malign kanser türüdür. Parietin genellikle ışkın (Rheum ribes L.) gibi bazı bitkilerden izole edilen bir antrakinondur. Sitotoksik ve genotoksik testler karsinojenik ve kalıtımsal risklerin değerlendirilmesinde önemli testlerdir. Bu çalışmada parietinin HepG2 hepatoselüler karsinom hücrelerinde sitotoksik ve genotoksik etkisinin araştırılması amaçlanmıştır. HepG2 hücreleri uygun koşullarda kültüre edildi. Daha sonra hücrelere 25-1000 μM aralığında konsantrasyonda parietin uygulanarak 24-48 saat inkübasyona bırakıldı. Hücre canlılık oranı XTT yöntemi ile doza ve zamana bağlı olarak belirlendi. Genototoksik etkisi ise komet yöntemi ile belirlendi. Elde edilen veriler istatiksel olarak değerlendirildi. Parietinin HepG2 hücrelerine IC50 değeri 48. saatte 25 μM olarak belirlendi. Komet analiz sonuçlarına göre DNA kuyruk uzunluğu, kuyruk yoğunluğu ve kuyruk momenti gibi parametrelerde istatistiksel olarak anlamlı bir artış görülmedi (p>0.05). Bu çalışmada, parietinin HepG2 hücrelerinde düşük konsantrasyonda sitotoksik etki gösterdiği fakat genotoksik etki göstermediği gösterilmiştir. Sonuç olarak parietin, hepatoselüler karsinom tedavisinde diğer ilaçlarla birlikte kombine olarak faydalı bir ajan olabileceği öngörülmekle birlikte ve yapılacak olan daha detaylı çalışmalarla da desteklenmelidir.

🔖

Cite This Article

DEMİRKAYA, A. K., GÜNDOĞDU, G., DODURGA, Y., SEÇME, M., GÜNDOĞDU, K. (2019). Determination of Cytotoxic and Genotoxic Effects of Parietin in HepG2 Hepatocellular Carcinoma Cells. Veterinary Sciences and Practices, Cilt: 14 Sayı: 1, 29–37. https://ajindex.com/articles/917590

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Kutluk T., Kars A., Kanser konusunda güncel Bilgiler. T.C. Sağlık Bakanlığı Sağlık Projesi Genel Koordinatörlüğü Kanser ve Savaş Daire Başkanlığı, Ankara.2. WHO, 2017. Guide to cancer early diagnosis. World Health Organization Document Production Services, Geneva, Switzerland.3. IARC, 2014.
  2. Bernard WS, Chistoper PW. World Cancer Report, 630, ISBN-13 9789283204299.4. Merlo LM., Pepper JW., Reid BJ., Maley CC., 2006. Cancer as an Evolutionary and Ecological Process. Nat Rev Cancer, 6, 924-935.5. Guyton AC., Hall JE., 2001.
  3. Protein Sentezi, Hücre Fonksiyonu ve Hücre Çoğalmasinin Genetik Kontrolü. In “Tıbbi Fizyoloji”, Ed., H Çavuşcuoğlu, 10th ed., 24-37,
  4. Nobel Tıp Kitapevleri Ltd Şti, Ankara.6. Hanahan D., Weinberg RA., 2011. Hallmarks of Cancer: The Next Generation. Cell, 144(5), 646-674.7. Lodish H., Berk A., Kaiser CA., Krieger M., Scott MP., Bretscher A., Ploeg H., Matsudaira P., 2008. Molecular Cell Biology. 6th. Edititon. 1107-1108,
  5. W.H.Freeman and Company, New York.8. Türker FA., Kayaalp SO., 2002. Kanser Kemoterapisinin Esasları ve Antineoplastik Ilaçlar. 380-415,
  6. Feryal Matbaacılık, Ankara.9. Tozkoparan B., Aytaç SP., 2007. Kanser Kemoterapisinde Terapötik Hedef Olarak Gluatatyon S-Transferazlar. Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi, 27, 139-164.10. Roy-byrne PP., Bystritsky A., Russo J., Craske MG., Sherbourne CD., Stein MB., 2005. Use of Herbal Medicine in Primary Care Patients with Mood and Anxiety Disorders. Psychosomatics, 46, 117–122.11. Steinmetz KA., Potter JD., 1991.
  7. Vegetables, Fruit, and Cancer. II. Mechanisms. Cancer Causes Control, 2(6), 427-42.12. Ziegler RG., Colavito EA., Hartge P., McAdams MJ., Schoenberg JB., Mason TJ., Fraumeni JF., 1996. Importance of alpha-carotene, beta-carotene, and other Phytochemicals in The Etiology of Lung Cancer. Natl Cancer Inst, 9, 612-5.13. Jemal A., Bray F., Center MM., Ferlay J., Ward E., Forman D., 2011. Global cancer statistics. Cancer Journal of Clinicians, 61 (2), 69–90.14. Athar M., Back JH., Tang X., Kim KH., Kopelovich L., Bickers DR., Kim AL., 2007. Resveratrol: A Review of Preclinical Studies for Human Cancer Prevention. Toxicology and Applied Pharmacology, 224 (3), 274-83.15. Venugopal R., Liu RH., 2012. Phytochemicals in Diets For Breast Cancer Prevention: The Importance of Resveratrol and Ursolic Acid. Food Science and Human Wellness, 1 (1), 1-13.16. Singh CK., George J., Ahmad N., 2013. Resveratrol-based Combinatorial Strategies for Cancer Management. Annals of the New Yo